# NCT03832569 (NCT03832569)

> Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03832569
- Phase: EARLY_PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Memorial Sloan Kettering Cancer Center
- Conditions: Solid Tumors; Identified by NGS, PCR or IHC
- Interventions: Pembrolizumab
- Enrollment: 17
- Primary outcome: proportion of patients with ctDNA clearance

## Indexed commentary on NCT03832569 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03832569